In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products

被引:189
作者
Diomede, L
Albani, D
Sottocorno, M
Donati, MB
Bianchi, M
Fruscella, P
Salmona, M
机构
[1] Ist Ric Farmacol Mario Negri, Dept Mol Biochem & Pharmacol, I-20157 Milan, Italy
[2] Consorzio Mario Negri Sud, Dept Med & Vasc Pharmacol, Chieti, Italy
关键词
statins; HMG-CoA reductase; squalene synthetase; interleukin-6; chemokines;
D O I
10.1161/hq0801.094222
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This study set out to clarify whether the inhibition of sterol or nonsterol derivatives arising from mevalonate biotransformation plays a major role in the in vivo anti-inflammatory action of statins. Hepatic synthesis of all these derivatives was inhibited in mice by administered statins, whereas squalestatin inhibited only sterol derivatives. Using a short-term treatment schedule, we found that statins reduced the hepatic activity of 3-hydroxy-3-methylglutaryl coenzyme A reductase without affecting blood cholesterol. This treatment inhibited lipopolysaccharide- and carrageenan-induced pouch leukocyte recruitment and the exudate production of interleukin-6, monocyte chemotactic protein-1, and RANTES. Coadministration of mevalonate reversed the effect of statin on leukocyte recruitment. The inhibition of sterol synthesis by squalestatin did not have any anti-inflammatory effect, indicating that the biosynthesis of nonsterol compounds arising from mevalonate is crucial for the in vivo regulation of cytokine and chemokine production by statins. Their inhibition by statins may account for the reported anti-inflammatory effects of these drugs and may provide a biochemical basis for the recently reported effects of statins in the prevention of cardiovascular disease and mortality.
引用
收藏
页码:1327 / 1332
页数:6
相关论文
共 39 条
  • [1] Endogenous monocyte chemoattractant protein-1 recruits monocytes in the zymosan peritonitis model
    Ajuebor, MN
    Flower, RJ
    Hannon, R
    Christie, M
    Bowers, K
    Verity, A
    Perretti, M
    [J]. JOURNAL OF LEUKOCYTE BIOLOGY, 1998, 63 (01) : 108 - 116
  • [2] BAXTER A, 1992, J BIOL CHEM, V267, P11705
  • [3] Lipid-lowering drugs in the management of hyperlipidaemia
    Bhatnagar, D
    [J]. PHARMACOLOGY & THERAPEUTICS, 1998, 79 (03) : 205 - 230
  • [4] Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis
    Boring, L
    Gosling, J
    Cleary, M
    Charo, IF
    [J]. NATURE, 1998, 394 (6696) : 894 - 897
  • [5] CORSINI A, 1995, AM J CARDIOL, V76, pA21
  • [6] Diomede L., 1999, European Journal of Clinical Investigation, V29, P43
  • [7] Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels - Results of AFCAPS/TexCAPS
    Downs, JR
    Clearfield, M
    Weis, S
    Whitney, E
    Shapiro, DR
    Beere, PA
    Langendorfer, A
    Stein, EA
    Kruyer, W
    Gotto, AM
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (20): : 1615 - 1622
  • [8] Inhibition of HMG-CoA reductase activity by hypercholesterolaemia reduces leukocyte recruitment and MCP-1 production
    Fruscella, P
    Romano, M
    Albani, D
    Bernasconi, S
    Luini, W
    Bruno, A
    Salmona, M
    Diomede, L
    [J]. CYTOKINE, 2000, 12 (07) : 1100 - 1103
  • [9] REGULATION OF THE MEVALONATE PATHWAY
    GOLDSTEIN, JL
    BROWN, MS
    [J]. NATURE, 1990, 343 (6257) : 425 - 430
  • [10] Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice
    Gu, L
    Okada, Y
    Clinton, SK
    Gerard, C
    Sukhova, GK
    Libby, P
    Rollins, BJ
    [J]. MOLECULAR CELL, 1998, 2 (02) : 275 - 281